View source for Template:Estrogen dosages for prostate cancer

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Estrogen dosages for prostate cancer|mini=y}} <noinclude>[[Chemistry:Estrogen (medication)|Estrogen]]</noinclude><includeonly>Estrogen</includeonly> dosages for <noinclude>[[prostate cancer]]</noinclude><includeonly>prostate cancer</includeonly>
|-
! Route/form !! Estrogen !! Dosage <noinclude>!! Ref(s)</noinclude>
|-
| rowspan="11" | [[Medicine:Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || 1–2 mg 3x/day <noinclude> || <ref name="Estrace-FDA-Label-2005">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf</ref></noinclude>
|-
| {{No selflink|Conjugated estrogens}} || 1.25–2.5 mg 3x/day <noinclude> || <ref name="ThomasKeenan1986">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Oettel1999">{{cite book|last1=Oettel|first1=M|chapter=Estrogens and Antiestrogens in the Male|pages=505–571|doi=10.1007/978-3-642-60107-1_25|editor1=Michael Oettel|editor2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA538|date=1999|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|issn=0171-2004}}</ref></noinclude>
|-
| {{No selflink|Ethinylestradiol}} || 0.15–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Oettel1999" /><ref name="Martz2013">{{cite book|author=G. Martz|title=Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms|url=https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA51|date=13 March 2013|publisher=Springer-Verlag|isbn=978-3-642-86282-3|pages=51–}}</ref></noinclude>
|-
| {{No selflink|Ethinylestradiol sulfonate}} || 1–2 mg 1x/week <noinclude> || <ref name="HöflingHeynemann2014">{{cite journal|last1=Höfling|first1=G.|last2=Heynemann|first2=H.|title=Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?|trans-title=Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?|journal=Der Urologe B|volume=38|issue=2|year=2014|pages=165–170|issn=0042-1111|doi=10.1007/s001310050185}}</ref><ref name="Oettel1999" /><ref name="HinkelbeinMiller2013">{{cite book|author1=Wolfgang Hinkelbein|author2=Kurt Miller|author3=Thomas Wiegel|title=Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte|url=https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA91|date=7 March 2013|publisher=Springer-Verlag|isbn=978-3-642-60064-7|pages=91–}}</ref></noinclude>
|-
| {{No selflink|Diethylstilbestrol}} || 1–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Lupulescu1990">{{cite book|author=Aurel Lupulescu|chapter=Hormones and Hormonotherapy|title=Hormones and Vitamins in Cancer Treatment|url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57|date=24 October 1990|publisher=CRC Press|isbn=978-0-8493-5973-6|pages=33–90}}</ref></noinclude>
|-
| {{No selflink|Dienestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982">{{cite book|author1=Günther H. Jacobi|author2=Rudolf Hohenfellner|title=Prostate Cancer|url=https://books.google.com/books?id=4HNrAAAAMAAJ|date=1 December 1982|publisher=Williams & Wilkins|isbn=978-0-683-04354-9|page=223}}</ref></noinclude>
|-
| {{No selflink|Hexestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>
|-
| {{No selflink|Fosfestrol}} || 100–480 mg 1–3x/day <noinclude> || <ref name="Martindale-Fosfestrol">{{cite book |editor=Sweetman, Sean C. |chapter=Sex hormones and their modulators |title=Martindale: The Complete Drug Reference |edition=36th |year=2009 |page=2104–2105 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|url=https://www.medicinescomplete.com/mc/martindale/}}</ref><ref name="BruchhausenDannhardt2013">{{cite book |author=Franz von Bruchhausen|author2=Gerd Dannhardt|author3=Siegfried Ebel|author4=August W. Frahm |author5=Eberhard Hackenthal |author6=Ulrike Holzgrabe |title=Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O|url=https://books.google.com/books?id=8vSjBgAAQBAJ&pg=PA301|date=2 July 2013|publisher=Springer-Verlag|isbn=978-3-642-57994-3|pages=301–}}</ref><ref name="Martz2013" /></noinclude>
|-
| {{No selflink|Chlorotrianisene}} || 12–48 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="JacobiHohenfellner1982" /><ref name="Dao1975">{{cite book | last1 = Dao | first1 = Thomas L. | chapter = Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms | year = 1975 | pages = 170–192 | doi = 10.1007/978-3-642-65806-8_11 | editor1 = Alan C. Sartorelli | editor2 = David G. Johns | title = Antineoplastic and Immunosuppressive Agents | url = https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 | isbn = 978-3-642-65806-8}}</ref><ref name="Martz2013" /></noinclude>
|-
| {{No selflink|Quadrosilan}} || 900 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>
|-
| {{No selflink|Estramustine phosphate}} || 140–1400 mg/day <noinclude> || <ref name="pmid7579781">{{cite journal | vauthors = Perry CM, McTavish D | title = Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer | journal = Drugs Aging | volume = 7 | issue = 1 | pages = 49–74 | date = July 1995 | pmid = 7579781 | doi = 10.2165/00002512-199507010-00006 | url = }}</ref></noinclude>
|-
| [[Medicine:Transdermal patch|Transdermal patch]] || {{No selflink|Estradiol (medication)|Estradiol}} || 2–6x 100 μg/day<br />''Scrotal:'' 1x 100 μg/day <noinclude> || <ref name="pmid17019433">{{cite journal | vauthors = Ockrim J, Lalani EN, Abel P | title = Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy | journal = Nat Clin Pract Oncol | volume = 3 | issue = 10 | pages = 552–63 | date = October 2006 | pmid = 17019433 | doi = 10.1038/ncponc0602 | url = }}</ref><ref name="pmid12686820">{{cite journal | vauthors = Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD | title = Transdermal estradiol therapy for advanced prostate cancer--forward to the past? | journal = J. Urol. | volume = 169 | issue = 5 | pages = 1735–7 | date = May 2003 | pmid = 12686820 | doi = 10.1097/01.ju.0000061024.75334.40 | url = }}</ref><br /><ref name="ReAsenjo2005">{{cite journal | vauthors = Re I, Asenjo G, Maximino G, Micheletti L | title = Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE) | trans-title = Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer | language = Spanish | date = 2005 | journal = Revista Argentina de Urología | volume = 70 | issue = 4 | page = 231 | issn = 0325-2531 | doi = | pmid = | url = https://www.sau-net.org/publicaciones/abstracts_70_4.html}}</ref></noinclude>
|-
| rowspan="6" | {{abbrlink|IM|Intramuscular}} or [[Medicine:Subcutaneous injection|{{abbr|SC|subcutaneous}} injection]] || {{No selflink|Estradiol benzoate}} || 1.66 mg 3x/week <noinclude> || <ref name="NNR1949" /></noinclude>
|-
| {{No selflink|Estradiol dipropionate}} || 5 mg 1x/week <noinclude> || <ref name="NNR1949">{{cite journal|title=NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry|journal=Journal of the American Pharmaceutical Association (Practical Pharmacy ed.)|volume=10|issue=11|year=1949|pages=692–694|issn=00959561|doi=10.1016/S0095-9561(16)31995-8}}</ref></noinclude>
|-
| {{No selflink|Estradiol valerate}} || 10–40 mg 1x/1–2 weeks <noinclude> || <ref name="Delestrogen-Label">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009402s052lbl.pdf</ref><ref name="KohliAlikhan2004">{{cite journal | last1 = Kohli | first1 = M. | last2 = Alikhan | first2 = M. A. | last3 = Spencer | first3 = H. J. | last4 = Carter | first4 = G. | title = Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer | journal = Journal of Clinical Oncology | volume = 22 | issue = 14_suppl | year = 2004 | pages = 4726–4726 | issn = 0732-183X | doi = 10.1200/jco.2004.22.90140.4726}}</ref></noinclude>
|-
| {{No selflink|Estradiol undecylate}} || 100 mg 1x/4 weeks <noinclude> || <ref name="pmid18268497" /><ref name="JacobiHohenfellner1982" /></noinclude>
|-
| {{No selflink|Polyestradiol phosphate}} || ''Alone:'' 160–320 mg 1x/4 weeks<br />''With oral {{abbr|EE|ethinylestradiol}}:'' 40–80 mg 1x/4 weeks <noinclude> || <ref name="Pharmanovia">http://pharmanovia.com/product/estradurin/</ref><ref name="pmid18268497">{{cite journal | vauthors = Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, Sydes MR, Abel P, Eastwood AJ | title = Parenteral oestrogen in the treatment of prostate cancer: a systematic review | journal = Br. J. Cancer | volume = 98 | issue = 4 | pages = 697–707 | date = February 2008 | pmid = 18268497 | pmc = 2259178 | doi = 10.1038/sj.bjc.6604230 | url = }}</ref><br /><ref name="pmid7500443">{{cite journal | vauthors = Cox RL, Crawford ED | title = Estrogens in the treatment of prostate cancer | journal = J. Urol. | volume = 154 | issue = 6 | pages = 1991–8 | date = December 1995 | pmid = 7500443 | doi = 10.1016/s0022-5347(01)66670-9 | url = }}</ref><ref name="JacobiHohenfellner1982" /></noinclude>
|-
| {{No selflink|Estrone (medication)|Estrone}} || 2–4 mg 2–3x/week <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Estrone-FDA-Review-1979">https://www.accessdata.fda.gov/drugsatfda_docs/anda/pre96/85239_Estrone%20Suspension_Prntlbl.pdf</ref></noinclude>
|-
| rowspan="2" | [[Intravenous injection|{{abbr|IV|Intravenous}} injection]] || {{No selflink|Fosfestrol}} || 300–1200 mg 1–7x/week <noinclude> || <ref name="Martindale-Fosfestrol" /><ref name="BruchhausenDannhardt2013" /><ref name="Martz2013" /></noinclude>
|-
| {{No selflink|Estramustine phosphate}} || 240–450 mg/day <noinclude> || <ref name="pmid7579781" /><ref name="pmid9515186">{{cite journal | vauthors = Bergenheim AT, Henriksson R | title = Pharmacokinetics and pharmacodynamics of estramustine phosphate | journal = Clin Pharmacokinet | volume = 34 | issue = 2 | pages = 163–72 | date = February 1998 | pmid = 9515186 | doi = 10.2165/00003088-199834020-00004 | url = }}</ref></noinclude>
|- class="sortbottom"
| colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Note:''' Dosages are not necessarily equivalent.<includeonly> '''Sources:''' See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for breast cancer]]
* [[Template:Estrogen dosages for menopausal hormone therapy]]
* [[Template:Medications and dosages used in hormone therapy for transgender women]]

==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>